Cochrane COVID-19 Studienregister
Studienbericht
NCT05074433Erstmals veröffentlicht: 2021 Okt 12Letzte Aktualisierung: 2021 Okt 12

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants

  1. Studientyp
  2. Interventional
  1. Studienziel
  2. Prevention
  1. Studiendesign
  2. Other
  1. Interventionszuordnung
  2. Randomised
Referenzdatensätze

A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

Regeneron Pharmaceuticals
Erstmals veröffentlicht (first received 2021 October 12)ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT05074433)
Eintrag in Studienregister
Keine Ergebnisse
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants. The secondary objectives of the study are: - To evaluate the safety and tolerability of repeated SC injections of casirivimab+imdevimab in the study population - To characterize concentrations of casirivimab and imdevimab in serum over time - To assess the immunogenicity of casirivimab and imdevimab